-
Although sudden cardiac death has been garnering the major headlines - both positive and negative - and has spawned the approximately $4 billion domestic implantable cardioverter-defibrillator (ICD) industry, atrial fibrillation (AF) is increasingly gaining recognition in the cardiology world.
-
AGA Medical (Golden Valley, Minnesota) reported enrollment of the first patients in its newest clinical trial - PRIMA (Patent foramen ovale closure Reduction In Migraine with Aura) - intended to examine the connections between
-
Raising money in a field that has been over-hyped - such as biologics - isn't easy, according to David Ringler, head of corporate communications for Theregen (San Francisco).
-
Athersys (Cleveland) reported that the Addvance division of Angiotech Pharmaceuticals (Vancouver, British Columbia) has made an investment in the company to support the development of cell-based products for treating cardiovascular disease.
-
A new study has found that seeing the build-up of plaque in their own arteries is the incentive patients need to comply with doctor's orders. The study, conducted at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed) and
-
Gerald Wolf, PhD, MD, joined Advanced Magnetics (Cambridge, Massachusetts) as vice president of imaging. He also is an emeritus professor of radiology at Harvard Medical School. Advanced Magnetics develops nano-particle technology.
-
Medtronic (Minneapolis) has launched a clinical trial for a new heart failure (HF) device that combines the capabilities of an implantable cardioverter defibrillator (ICD) with a monitoring technology that continuously records pressure
-
Hurricane threats have become so common in recent years for Louisiana coastal residents that when state STD and HIV government officials closed their office doors in New Orleans on the Friday before Hurricane Katrina struck, they were convinced they would be returning on Monday morning to do business as usual.
-
The FDA is issuing guidance to sponsors on initiation of HIV vaccine studies involving pediatric patients. The guidance also provides recommendations to investigators and institutional review boards (IRBs) involved with such studies.
-
